[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9508927A - Processo para a preparação de compostos e composto - Google Patents

Processo para a preparação de compostos e composto

Info

Publication number
BR9508927A
BR9508927A BR9508927A BR9508927A BR9508927A BR 9508927 A BR9508927 A BR 9508927A BR 9508927 A BR9508927 A BR 9508927A BR 9508927 A BR9508927 A BR 9508927A BR 9508927 A BR9508927 A BR 9508927A
Authority
BR
Brazil
Prior art keywords
compost
compounds
preparation
Prior art date
Application number
BR9508927A
Other languages
English (en)
Inventor
Richard Desmond
Ulf Dolling
Ben Marcune
Richard Tillyer
David Tschaen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9508927A publication Critical patent/BR9508927A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BR9508927A 1994-09-16 1995-09-12 Processo para a preparação de compostos e composto BR9508927A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/307,972 US5585504A (en) 1994-09-16 1994-09-16 Process of making cox-2 inhibitors having a lactone bridge
PCT/US1995/011539 WO1996008482A1 (en) 1994-09-16 1995-09-12 Process for making phenyl heterocycles useful as cox-2 inhibitors

Publications (1)

Publication Number Publication Date
BR9508927A true BR9508927A (pt) 1997-12-30

Family

ID=23191976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508927A BR9508927A (pt) 1994-09-16 1995-09-12 Processo para a preparação de compostos e composto

Country Status (12)

Country Link
US (1) US5585504A (pt)
CN (1) CN1065533C (pt)
AU (1) AU3510595A (pt)
BR (1) BR9508927A (pt)
CZ (1) CZ288797B6 (pt)
FI (1) FI106376B (pt)
RO (1) RO118585B1 (pt)
RU (1) RU2160257C2 (pt)
SK (1) SK282789B6 (pt)
TW (1) TW325468B (pt)
UA (1) UA49809C2 (pt)
WO (1) WO1996008482A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041516A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. (methylsulfonyl)phenyl-2-(5h)-furanones with oxygen link as cox-2 inhibitors
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
FR2747123B1 (fr) * 1996-04-04 1998-06-26 Union Pharma Scient Appl Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
HRP970289A2 (en) * 1996-05-31 1998-04-30 Merck & Co Inc Process for preparing phenyl heterocycles useful as cox-2 inhibitors
US5985930A (en) 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
WO1998037235A1 (en) 1997-02-24 1998-08-27 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
AU778538B2 (en) * 1999-03-10 2004-12-09 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
ES2208227T3 (es) 1999-12-03 2004-06-16 Pfizer Products Inc. Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
ES2200787T3 (es) 1999-12-03 2004-03-16 Pfizer Products Inc. Derivados de acetileno como agentes antiinflamatorios/analgesicos.
KR20020058074A (ko) 1999-12-03 2002-07-12 데이비드 존 우드 소염진통제로서의 헤테로시클로-알킬술포닐 피라졸 유도체
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
BR0008060A (pt) 1999-12-08 2002-02-05 Pharmacia Corp Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
DE10012825B4 (de) * 2000-03-16 2004-04-15 Bayer Corp. Verfahren zur Herstellung von spirocyclischen Tetronsäurederivaten
CN1102586C (zh) * 2000-04-07 2003-03-05 中国科学院上海有机化学研究所 β位含有芳基取代基的γ－丁烯酸内酯及其固相合成法
US20020128267A1 (en) * 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
ATE298749T1 (de) 2001-07-05 2005-07-15 Pfizer Prod Inc Heterocyclo-alkylsulfonyl pyrazole als entzündungshemmende/analgetische mittel
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
SI2266584T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S, Symbion Sestavek s stroncijem in vitaminom D za profilakso in/ali zdravljenje patologij hrustanca in/ali kosti
EP1745791B1 (en) * 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
AU2003263582A1 (en) * 2003-08-14 2005-03-07 Shasun Chemicals And Drugs Limited Process for the manufacture of rofecoxib
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293952A1 (en) * 1993-01-15 1994-07-21 David B. Reitz Preparation of esters and analogs thereof
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
HUT74986A (en) * 1994-01-10 1997-03-28 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors, pharmaceutical preparations containing them, and use of them

Also Published As

Publication number Publication date
RU2160257C2 (ru) 2000-12-10
CN1159191A (zh) 1997-09-10
UA49809C2 (uk) 2002-10-15
RO118585B1 (ro) 2003-07-30
TW325468B (en) 1998-01-21
SK31697A3 (en) 1997-10-08
CZ288797B6 (cs) 2001-09-12
SK282789B6 (sk) 2002-12-03
FI971104A (fi) 1997-03-14
CN1065533C (zh) 2001-05-09
US5585504A (en) 1996-12-17
CZ79297A3 (en) 1997-07-16
WO1996008482A1 (en) 1996-03-21
AU3510595A (en) 1996-03-29
FI106376B (fi) 2001-01-31
FI971104A0 (fi) 1997-03-14

Similar Documents

Publication Publication Date Title
BR9508927A (pt) Processo para a preparação de compostos e composto
PT1256584E (pt) Processo para a preparacao de adefovir-dipivoxil
BR9505754A (pt) Processo para a preparação de copolímeros de poliéster
BR9710457A (pt) Processo para a prepara-Æo de ciclohexanodimetanol
PT770615E (pt) Processo para a preparacao de di-haloazolopirimidinas
BR9710104A (pt) Processo para a preparação de particulas políméricas
BR9510336A (pt) Processo para a síntese de polímeros composição e polímero
BR9404206A (pt) Processo para a preparação de um composto indanil-amina compostos intermediários e processo para a preparação de compostos intermediários
BR9711201A (pt) Processo para a prepara-ao de um composto
BR9500668A (pt) Processo para a preparaçao de compostos polialquil-1-oxa- diazaspirodecano
BR9508320A (pt) Processo para a preparação de um composto e cultura biologicamente
PT900254E (pt) Processo para a preparacao de composicoes de betume
BR9707811A (pt) Processo para preparação de um composto e composto
BR9301180A (pt) Processo para a preparacao de isocianatos e emprego
BR9500613A (pt) Processo para a preparação contínua de mononitrotoluenos
BR9400604A (pt) Processo para a preparação de 1,1,1,3,3-pentafluorpropano
BR9505251A (pt) Processo para a fabricação de um composto e composto obtido
BR9702047A (pt) Processo para a preparação de uréia granular
PT880498E (pt) Processo para a preparacao de compostos dicetonicos
BR9606204A (pt) Processo para a preparação de pentaeritritol
BR9301676A (pt) Processo para a preparacao de 1,1,1,4,4,4-hexafluorbutano e compostos obtidos
PT803576E (pt) Processo para a preparacao de lipstatina e de tetra-hidrolipstatina
BR9201995A (pt) Processo para obtencao de adubo
BR9711994A (pt) Compostos de beta-lactama e processo para a prepara-Æo dos mesmos
PT1012152E (pt) Processo para a preparacao de oxazafosforina-2-aminas

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements